Emergent Biosolutions is in the biotechnology industry and trades as part of the healthcare sector. The company CEO is Daniel J. Abdun-Nabi. Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. The company focuses on countermeasures that address public health threats around hematology and oncology therapeutics.
Previous Intraday Trading Performance:
The EBS stock showed a previous change of 1.91% with an open at 63.01 and a close of 63.90. It reached an intraday high of 64.40 and a low of 62.42.
The stock has a market cap of $3.3b with 50.9m shares outstanding, of which the float is 48.7m shares. Trading volume reached 413,140 shares compared to its average volume of 478,115 shares. Based on the current average volume and close price, the trading liquidity is good.
Historical Trading Performance:
Over the last five trading days, Emergent Biosolutions shares returned 11.05% and in the past 30 trading days it returned -9.39%. Over three months, it changed -1.45%. In one year it has changed 34.67% and within that year its 52-week high was 73.89 and its 52-week low was 42.67. EBS stock is 49.77% above its 52 Week Low.
Our calculations show a 200 day moving average of 58.14 and a 50 day moving average of 64.50. Currently EBS stock is trading 9.91% above its 200 day moving average.
The last annual fiscal EPS for the company was reported at 1.7 that ended on 31st of December 2017, which according to the previous close, that is a PE of 37.59. Based on 3 analyst estimates, the consensus EPS for the next quarter is 0.54. The TTM EPS is 2.33, which comes to a TTM PE of 27.42. Historically, the PE high was 49.00 and the PE low was 18.90. If the stock reached its PE low, that would represent a price of 44.04, which is a decrease of -31.07%.
The following are the last four quarter reported earnings per share:
Base on our calculations, the intrinsic value per share is 68.42, which means it is possibly undervalued and has a margin of safety of 6.61%
Indicators to Watch:
Based on the latest filings, there is 4.60% of insider ownership and 127.30% of institutional ownership. Short-interest is 2,152,188, which is 4.22% of shares outstanding. The short-interest ratio or days-to-cover ratio is 5.46. This stock has some short interest, but it may be normal and no cause for concern if long the position.
The current calculated beta is 1.48
Based on last reported financials, the company’s return on equity is 12.28%, return on assets is 9.11%, profit margin is 12.93%, price-to-sales is 6.24 and price-to-book is 3.10.
All scores are out of six:
0 :Valuation Score
3 :Past Performance Score
6 :Financial Strength Score
2 :Future Growth Score
0 :Dividend Score
2 :Overall Score